BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remi...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostics (Basel)
Main Authors: Bilbao-Sieyro, Cristina, Rodríguez-Medina, Carlos, Florido, Yanira, Stuckey, Ruth, Sáez, María Nieves, Sánchez-Sosa, Santiago, González Martín, Jesús María, Santana, Guillermo, González-Pérez, Elena, Cruz-Cruz, Naylén, Fernández, Rosa, Molero Labarta, Teresa, Gomez-Casares, María Teresa
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7762084/
https://ncbi.nlm.nih.gov/pubmed/33291851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics10121048
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items